Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences

PITTSBURGH – Jan. 3, 2023 – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7 as part of Viatris’…Read More

Read More
Soleno Therapeutics Announces Financing Commitment for up to $60 Million

REDWOOD CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a Securities Purchase Agreement with Nantahala Capital Management, LLC, Abingworth LLP and Vivo Capital, LLC for…Read More

Read More
Curevo Vaccine Announces $26M Series A-1 Financing

SEATTLE-November 16, 2022 -(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round. This brings total funding raised in 2022 to $86M for the…Read More

Read More
Saluda Medical Adds Laureen DeBuono to Board of Directors

ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors and Chair of the company’s Audit Committee….Read More

Read More
Rivus Pharmaceutical Closes $132M Series B

CHARLOTTESVILLE, Va., September 22, 2022 – Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi…Read More

Read More